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Abstract 
Structurally complex polyketide natural products, isolated from a variety of marine and 
terrestrial sources, continue to provide a valuable source of rewarding targets for the synthetic 
chemist to tackle. In this account, we provide an overview of the total synthesis of several 15 
structurally fascinating polyketides with promising anticancer activity completed in our group 
based on our versatile asymmetric aldol methodology – spirastrellolide A methyl ester, 
leiodermatolide, rhizopodin and chivosazole F – and highlight the unanticipated challenges 
and discoveries encountered. 
 20 
Introduction 
Through aeons of evolution, nature has gifted us with a seemingly limitless source of 
important secondary metabolites. Such compounds are often astoundingly intricate in terms of 
their molecular architecture, with stereochemically elaborate scaffolds that dwarf structures 
2 
conceived by mankind. Unsurprisingly, such extraordinary structures demand effective 25 
methodologies and strategies, along with hard work and perseverance, to ensure a successful 
outcome from a suitably focused synthetic campaign. Furthermore, the vanishingly low 
isolation yields of such natural products can preclude their full stereochemical assignment, 
rendering total synthesis a valuable tool for structural elucidation.1–5 
Amongst the vast chemical space carved out by nature are the polyketides, typified by 30 
their dazzling array of functionality and stereochemistry, providing a testing intellectual 
challenge for the synthetic chemist. Enticed by these intriguing structures, which generally have 
impressive biological activities,6 our group has had a longstanding interest in the development 
of novel synthetic methods and strategies that are both robust and, where required, flexible. In 
this context, the efficiency of our suite of versatile boron-mediated aldol reactions has proved 35 
invaluable for the controlled installation of the highly oxygenated frameworks of these 
captivating natural products.7–9  
In this account, we provide an overview of recent research endeavors that have culminated 
in the total synthesis of several challenging polyketide natural products with promising 
anticancer activity in our group: spirastrellolide A methyl ester (1), leiodermatolide (2), 40 
rhizopodin (3), and chivosazole F (4) (Figure 1). In particular, we highlight the unexpected 
obstacles encountered and subsequent discoveries that resulted in the successful total syntheses 
of these highly challenging targets. 
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Figure 1. Structures of spirastrellolide A methyl ester (1), leiodermatolide (2), rhizopodin (3) and 
chivosazole F (4) 
 
Spirastrellolide A methyl ester  
The spirastrellolides constitute an extraordinary family of spiroacetal macrolides first 50 
isolated by Andersen and co-workers in 2003 from extracts of the Caribbean sponge 
Spirastrella coccinea.10 The most abundant congener, spirastrellolide A (1) (isolated as the 
corresponding methyl ester) exhibits striking structural complexity, containing 20 
stereocentres, a 38-membered macrolactone and a nine-carbon side chain featuring a (Z,E)-
1,4-diene.11–15 The macrocycle itself contains a tetrahydropyran (A ring), a bicyclic 6,6-55 
spiroacetal (BC rings) and a tricyclic 5,6,6-spiroacetal (DEF rings) featuring a chlorine atom 
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at C28. Additionally, spirastrellolide A was found to exhibit potent antimitotic properties via 
selective protein phosphatase 2A inhibition (IC50 = 1 nM).10,12 Beyond the obvious potential 
as a novel anticancer lead, such phosphatase inhibitors have also shown therapeutic promise 
in tackling obesity, autoimmune conditions and neurodegenerative disorders.16 The 60 
combination of the synthetic challenge posed by their architectural complexity and promising 
biological activity has rendered the spirastrellolides the focus of intense research efforts from 
numerous groups.15 Despite this, only five completed syntheses have been reported to date,17–
20 two of which are from our group.21–24 
Our efforts towards spirastrellolide A methyl ester began soon after disclosure of the 65 
originally proposed structure and our synthetic approach evolved concurrently with structural 
determination studies on this moving target.25 A flexible endgame was a strict requirement as 
a consequence of the ambiguity surrounding the C46 hydroxyl stereocentre. Specifically, our 
initial strategy in face of these imposed requirements involved a modular approach to 
macrocycle formation, resulting in the successful assembly of the complete ABCDEF ring 70 
system, followed by late-stage side chain attachment to facilitate preparation of both possible 
C46 diastereomers.26 
With advanced intermediate 5 (Scheme 1) in hand after a sustained campaign of 
dedicated efforts,22,26 synthesis completion appeared tantalisingly close. Unfortunately, 
selective removal of the C40 silyl protecting group to enable side chain incorporation proved 75 
to be a major obstacle. In the end, a global deprotection, followed by protecting group 
adjustment, was required. Oxidation to the corresponding aldehyde 6 then proceeded smoothly 
and set the scene for homologation. At this point, a variety of organometallic addition 
reactions were trialled unsuccessfully. We surmised that these failures were likely to be a 
reflection of the steric constraints imposed on the C40 aldehyde by the proximal cage-like 80 
macrocycle. After exhaustive experimentation, it was found that a simple Wittig olefination 
5 
reaction could be used to access a terminal alkene, thereby allowing side chain incorporation 
via olefin cross-metathesis.27,28 After considerable experimentation, the cross-metathesis with 
dicarbonate 7 required relatively forcing conditions (refluxing in benzene), due to the steric 
constraints imposed by the macrocycle. The resulting allylic carbonate 8 then allowed a π-85 
allyl Stille cross-coupling with stannane 9 to afford the bis-acetonide protected natural 
product, which underwent a global deprotection to afford the first total synthesis of 
spirastrellolide A methyl ester (1).22 Notably, the 46-epi diastereomer of 1 showed distinctly 
different NMR spectra due to the influence of the proximate macrocycle. 
 90 
 
Scheme 1. Endgame sequence for the first-generation synthesis of spirastrellolide A methyl ester (1) 
Having successfully completed the target molecule, and thereby validating the 
configurational assignment, we next sought to improve our synthesis, paying specific attention 
to avoiding unnecessary redox steps and protecting group manipulations. In particular, the 95 
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need for a divergent side-chain installation strategy was now deemed unnecessary with the 
stereochemistry of the natural product now unambiguously assigned. Additionally, we sought 
to capitalise on the availability of key fragments from our first-generation approach, giving 
rise to the revised retrosynthetic analysis in Scheme 2. Notably, we looked to establish the 
C1-C47 carbon backbone in 10 (from allylic carbonate 11 and stannane 12) in its entirety prior 100 
to macrolactonisation, thereby simplifying incorporation of the (E,Z)-skipped diene side 
chain. Building on earlier work, the BC spiroacetal moiety would be installed through PMB 
deprotection/in situ spiroacetalisation of a Z-enone arising from coupling of the C1-C16 
alkyne fragment 13 and C17-C40 aldehyde 14.26 Disconnection across C24-C25 via an sp3-
sp2 Suzuki coupling29 then reveals two intermediates utilised previously, C17-C24 vinyl 105 
iodide 15 and C25-C40 bis-spiroacetal 16.30  
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Scheme 2. Revised retrosynthesis of spirastrellolide A methyl ester (1) 
In our first-generation synthesis, the construction of the C26-C40 DEF bis-spiroacetal 
17 via an acid-mediated deprotection/spiroacetalisation cascade of 18 was a major 110 
bottleneck.31 The problem stemmed from formation of the undesired furan 19 via competing 
elimination (Scheme 3A). Even after extensive optimisation, we could only generate a modest 
amount of the required C26-C40 DEF bis-spiroacetal 17. Thus, we needed to revise our 
strategy in order to achieve a reliable multigram supply of this essential fragment. Firstly, we 
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8 
removed the appended g-lactone in a bid to avoid competitive furan formation. Additionally, 115 
we noted that the bis-spiroacetal could arise from a tetraol linear precursor. In particular, we 
recognised that the sense of asymmetric induction via the Sharpless asymmetric 
dihydroxylation required to install the C37/C38 and C26/C27 hydroxyls was the same. This 
led to an adventurous double dihydroxylation/spiroacetalisation cascade as in 20 to 21, which, 
if successful, would provide an elegant and efficient synthesis of the DEF bis-spiroacetal ring 120 
system (Scheme 3B). 
 
 
Scheme 3. A) First-generation approach towards the C26-C40 DEF bis-spiroacetal 17. B) Revised strategy towards 
the C26-C40 DEF bis-spiroacetal 21 125 
The required linear precursor 20 (Scheme 4) was readily prepared from aldehyde 22 and 
ketone 23, notably employing an Oehlschlager-Brown syn-choroallylation32 and our lactate 
aldol methodogy33 to set up the required stereocentres.24 A boron-mediated aldol reaction 
facilitated the fragment union to form b-hydroxyketone 24, which led onto the required linear 
precursor 20 via a four-step sequence.30 At this stage, we attempted the pivotal double 130 
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9 
asymmetric dihydroxylation.34 This initially afforded bis-hemiacetal 25, which to our delight 
spirocyclised under mild acidic conditions to afford the DEF-bis-spiroacetal 21. Fortuitously, 
we discovered that other spirocyclic isomers of 21 could be resubmitted under acidic 
conditions to afford the required DEF bis-spiroacetal cleanly. This was only made possible by 
the increased stability of the DEF bis-spirocycle circumventing furan formation, giving us the 135 
opportunity to employ thermodynamic equilibration rather than kinetic control. A final bis-
silylation delivered the protected fragment 26 efficiently. Most importantly, this route 
facilitated a dependable multigram scale synthesis of the crucial C26-C40 bis-spiroacetal 
moiety. 
10 
 140 
Scheme 4. Revised synthesis of the C26-C40 DEF bis-spiroacetal 26 
 
Armed with an efficient and scalable route towards C1-C16 alkyne 13, C17-24 vinyl 
iodide 15 and now the C26-C40 bis-spiroacetal 26,26,30 we set out to improve the fragment 
coupling sequence (Scheme 5).35 Preparation of C17-C40 aldehyde 14 commenced with a 145 
primary TES deprotection, oxidation and methylenation to provide the corresponding C25-
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C40 alkene 16. Hydroboration of 16 followed by an in situ sp3-sp2 Suzuki cross-coupling with 
vinyl iodide 15 forged the C24-C25 bond and furnished diene 27 cleanly.29,36 The final two 
stereocentres of the C17-C40 fragment were set up via a diastereoselective substrate-
controlled double hydroboration sequence; installing the C17 and C23 hydroxyl groups and 150 
affording the required 23,24-anti stereochemistry in 28. Protecting group manipulations then 
yielded an advanced triol, which was subjected to a selective triple oxidation of the two 
primary alcohols with concomitant lactonisation to afford the required C17-C40 aldehyde 14. 
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Scheme 5. Synthesis of the C17-C40 aldehyde 14 
 
Our initial coupling strategy to form the C16-C17 bond hinged upon an the addition  of 
an alkynyllithium species to the C17 aldehyde.26 However, this transformation now proved to 
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be capricious owing to competing addition to the γ-lactone moiety. Instead, a Nozaki-Hiyama-160 
Kishi coupling37,38 between iodoalkyne 29 and aldehyde 14, to our delight, chemoselectively 
and reliably forged the C16-C17 bond (Scheme 6). The BC spiroacetal formation commenced 
with a Lindlar reduction of the alkyne 30 and oxidation to the Z-enone. Subsequent bis-PMB 
deprotection under controlled conditions set the scene for a concomitant acetalisation to 
cleanly forge the BC-spiroacetal ring system, now affording 31 with all the requisite ABCDEF 165 
rings in a stereodefined manner. With the carbon and oxygen skeleton for the macrocycle now 
in hand, our attention turned towards side chain installation and the final macrolactonisation. 
A selective primary TBS ether deprotection, partial reduction of the γ-lactone and vinylation 
afforded allylic alcohol 32, which was then treated with triphosgene to both temporarily mask 
the diol as well as providing the requisite leaving group for the π-allyl Stille cross-coupling. 170 
Pleasingly, the planned cross-coupling between allylic carbonate 11 and vinyl stannane 12 
proceeded efficiently, and was a major improvement over our previous cross-metathesis route 
in the presence of the full macrocycle. With only the macrolactonisation and global 
deprotection left, the finish line was now in sight. Once again, this transformation proved to 
be significantly more challenging than initially anticipated! 175 
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Scheme 6. Synthesis of the full C1-C47 carbon and oxygen skeleton of spirastrellolide A methyl ester 10 
Frustratingly, subjecting seco-acid 10 to increasingly forcing conditions (including 
refluxing in toluene) for macrolactonisation39,40 not only failed to furnish the cyclised product, 
but returned degraded starting material. We initially surmised that the side chain was perhaps 180 
impeding the macrolactonisation, however, diol 33 corresponding to the truncated macrocycle 
also failed to cyclise when subjected to previously established macrolactonisation conditions 
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14 
(Scheme 7A). This unexpected difficulty was in stark contrast to the highly efficient 
macrolactonisation (>95%) observed in our first-generation route (Scheme 7B), which we 
attributed to a degree of favourable conformational pre-organisation in the seco-acid 34. 185 
Comparison of the seco-acid 10 with that used previously highlighted only one seemingly minor 
structural difference – the (very distal) C23 TES ether. Therefore, we hypothesised that 
unfavourable conformational effects, presumably imposed by the additional silyl protecting 
group, were operating to bias the free acid away from ring closing with the C37 alcohol. As 
such, we treated seco-acid 10 with PPTS in methanol to effect controlled mono- and bis-TES 190 
ether cleavage. Our hypothesis was proven to be correct; submitting either of the mono- or bis-
desilylated products (35 and 36) to standard Yamaguchi macrolactonisation conditions now 
afforded macrocycles 37 and 38 in excellent yield (Scheme 7C). A final global deprotection 
completed our second-generation synthesis of spirastrellolide A methyl ester (1) in 23 linear 
steps and 6% overall yield from C26-C40 bis-spiroacetal 26. When compared with the first-195 
generation synthesis (25 steps and 1% overall yield), it is pleasing to note the improvement in 
efficiency, both in terms of step count and yield. Moreover, we discovered that we were 
incredibly lucky in our first-generation synthesis – where the troublesome C23-TES ether was 
unintentionally cleaved in the BC-spiroacetalisation step, which greatly assisted the crucial 
downstream macrolactonisation reaction. An important lesson was learned here, that protecting 200 
groups can have subtle and unpredictable conformational effects in such complex substrates! 
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Scheme 7. A) Truncated seco-acid 33 failed to macrocyclise when subjected to established 
macrolactonisation conditions B) Macrocyclisation conditions in our first-generation synthesis C) Endgame 
and total synthesis of spirastrellolide A methyl ester (1) 205 
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Leiodermatolide 210 
In 2008, leiodermatolide (2) was isolated from the lithistid sponge Leiodermatium sp. 
collected off the coast of Florida by the Wright group.41 Spectroscopic analysis illuminated 
the planar structure of 2 and revealed a 16-membered macrolactone containing a Z,Z-diene 
and a pendant carbamate group, as well as an E,E-diene on the side chain terminating in a d-
lactone. The assigned structure highlighted the presence of nine stereocentres; six of which lie 215 
in the macrocycle and three in the terminal d-lactone.42 Biological evaluation showed that 
leiodermatolide exhibited potent anticancer activity, in particular against a range of drug-
resistant cancer cell lines. While leiodermatolide-treated cells exhibited physiological 
responses often typified by tubulin-binding compounds, in vitro studies failed to show 
evidence for any direct tubulin interaction. As such, it was suggested that leiodermatolide 220 
acted via an indirect mechanism orthogonal to other known tubulin-targeting anticancer drugs, 
indicative of a promising anticancer drug candidate. 
Our involvement with leiodermatolide was borne from its initially inconclusive 
stereochemical assignment. In collaboration with the Wright group, extensive NMR 
spectroscopic analysis, molecular modelling and computational DP4 NMR predictions43 225 
allowed us to refine the structure to a single diastereomer for the C1-C16 macrocycle and the 
C21-C25 d-lactone with >99% probability. Unfortunately, the distal nature of the C21-C25 d-
lactone relative to the macrocycle precluded a conclusive determination of the stereochemistry 
between these two stereoclusters, leading to four candidate stereoisomers for the natural 
product. To definitively pin down the stereochemistry of 2, we embarked on a synthetic 230 
campaign geared towards confirming the 3D structure of the macrocycle followed by the full 
natural product. A synthesis-enabled stereochemical elucidation was a notion shared with 
other research groups,44,45 which, to date, has resulted in one other group successfully 
synthesising leiodermatolide.46,47 
17 
As the absolute configuration was unknown, we arbitrarily targeted ent-2 and its 235 
diastereomer for initial studies. Our initial approach towards 2 hinged upon a late-stage sp2-
sp2 Suzuki coupling across C17-C18 to allow the flexible appendage of both enantiomers of 
the C18-C25 d-lactone to the macrocycle, as shown in Scheme 8A. The C18-C25 d-lactone 
39 could be readily synthesised from either enantiomer of 40. We anticipated that the C1-C17 
macrocycle 41 could be constructed from a linchpin bis-halide fragment 42, leveraging the 240 
more reactive vinyl iodide to selectively engage in a Stille cross-coupling with C1-C11 vinyl 
stannane 43. 
In executing this approach (Scheme 8B), we discovered that the bis-TBS protection of 
the C7 and C9 hydroxyl groups required relatively forcing conditions to effect the second 
silylation at C7.48 This observation indicated the possibility of realising a site-selective C9 245 
carbamate installation in the endgame. Our resulting synthesis of the C1-C17 macrocycle 41 
confirmed our relative stereochemical assignment through spectroscopic correlations.48 
However, the specific rotation recorded for the macrocycle was opposite in sign to (–)-
leiodermatolide; tentatively suggesting that we may have embarked in the wrong enantiomeric 
series. Additionally, there were two key issues we needed to address in the evolution of our 250 
synthetic strategy. Firstly, while the semi-reduction of vinyl dibromide 44 to (Z)-vinyl 
bromide 45 proceeded smoothly, subsequent attempts at converting it into the vinyl stannane 
proved problematic. This involved cleavage of the C7 and C9-TBS ethers to afford diol 46, 
followed by stannylation under Wulff-Stille conditions49 to form stannane 43, albeit in a 
modest yield (Scheme 6B). Furthermore, despite preliminary results suggesting otherwise, 255 
our vision of a late-stage site-selective carbamate installation proved unrewarding; treatment 
of the macrocycle 47 with trichloroacetyl isocyanate50 resulted in a 3 : 2 mixture of 
regioisomeric products 41 and 48 that favoured the undesired C7 carbamate 48. Moreover, 
attempts at realising the key Suzuki coupling to afford the full leiodermatolide carbon skeleton 
18 
proved fruitless; vinyl bromide 41 was found to be unreactive under a variety of palladium-260 
catalysed conditions.51  
 
Scheme 8. A) Initial approach towards leiodermatolide (ent-2). B) Summary of our first-generation 
synthesis towards the C1-C17 macrocycle 41 
This intelligence gathering exercise prompted us to revise our synthetic strategy towards 265 
2, as highlighted in Scheme 9, and we instead looked towards forming the fully elaborated 
macrocycle via a late-stage macrolactonisation. As the C11-C12 bond was reliably installed 
via a Stille coupling, we sought to disconnect the molecule into the C1-C11 vinyl stannane 
ent-43 and the C12-C25 d-lactone 49. The C12-C25 fragment itself can then be constructed 
from vinyl iodide 50 and d-lactone ent-39, employing a Suzuki coupling to forge the C17-C18 270 
bond. Despite disappointing initial results, we remained optimistic about effecting a 
regioselective carbamate formation, thereby minimising protecting group manipulations. 
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Scheme 9. Revised retrosynthesis for leiodermatolide (2) 
 275 
Our revised synthesis of the C1-C11 stannane ent-43 commenced from the Weinreb 
amide 51 derived from (R)-Roche ester (Scheme 10). By trapping the kinetic Z-enolate of the 
derived ketone with Comins’ reagent52 followed by a Suzuki-type methylation of vinyl triflate 
52, we successfully formed the trisubstituted alkene 53.53 Employing methodology developed 
by our group, a lactate aldol reaction between (R)-lactate-derived ethyl ketone (R)-40 and 280 
aldehyde 54 readily afforded the required anti adduct 55 with excellent 
diastereoselectivity.33,54,55 A four-step sequence installed the requisite alkyne and removed the 
lactate auxiliary. The required 1,3-anti reduction on ynone 56 proved problematic; employing 
the Evans-Tishchenko56 protocol failed outright. Unfortunately, the Evans-Saksena 
reduction57 on the same substrate gave poor diastereoselectivity. This was rationalised based 285 
on the small size of the alkyne substituent, reducing its preference to occupy the equatorial 
position in the transition state. Based on this hypothesis, we looked towards increasing the 
steric bulk by preparing the Z-vinyl iodide 5758. Luckily, this drastically improved the 
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20 
selectivity of the 1,3-anti reduction via the Evans-Saksena protocol, completing the required 
stereotetrad in the C1-C11 fragment. Next, lithiation followed by trapping with tributyltin 290 
chloride proceeded smoothly to give the C1-C11 stannane 58. Gratifyingly, this route was a 
significant improvement over our initial approach (20% yield over 14 steps, versus 6% yield 
over 14 steps).48,59 
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Scheme 10. Synthesis of the C1-C11 vinyl stannane 58 
The C12-C17 vinyl iodide was constructed again using our lactate aldol methodology, 
furnishing 50 in four steps (via aldol adduct 59) from ethyl ketone (S)-40 (Scheme 11).33,54,55 
Synthesis of the C18-C25 d-lactone commenced with a boron-mediated aldol reaction 
between ketone (R)-40 and propanal, affording the required anti adduct 60. The d-lactone was 300 
constructed through a BF3·OEt2-mediated Mukaiyama aldol reaction between ketone 61 and 
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21 
silyl ketene acetal 62.8,60 This, followed by an acid-mediated lactonisation, delivered the d-
lactone 63, where the matched stereoinduction from 1,2-Felkin and 1,3-Evans polar models 
are mutually reinforcing.61 Subsequent silylation afforded the protected lactone 64, where a 
two-step sequence revealed the required vinyl boronate ent-39 in anticipation for the key 305 
cross-coupling.  
 
Scheme 11. Synthesis of the C12-C17 vinyl iodide 50 and C18-C25 d-lactone ent-39 
 
The planned Suzuki coupling could be effected between vinyl iodide 50 and vinyl 310 
boronate ent-39. Advantageously, we discovered that the fragment union could also be readily 
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22 
achieved with excellent geometrical control via the Heck reaction to deliver 65 (Scheme 12),62 
saving two steps in converting the alkene 64 to the vinyl boronate ent-39 (vide supra). A two-
step procedure revealed the required C12-C25 vinyl iodide 49, which underwent a facile Stille 
coupling63,64 with stannane 58 to establish 66, corresponding to the full carbon skeleton of 315 
leiodermatolide. Finally, a series of redox and protecting group manipulations revealed the 
seco-acid 67, which was efficiently macrocyclised under our preferred Yamaguchi 
conditions39 to generate the 16-membered macrolactone. 
With a global deprotection revealing the des-carbamoyl derivative of leiodermatolide 
68, all that was required was the pivotal regioselective C9 carbamoylation. We surmised that 320 
the steric hindrance around C7 should heighten the reactivity of the C9 alcohol, a rationale 
supported by molecular modelling studies. As previously alluded to, treating the truncated 
macrolactone 47 with trichloroacetyl isocyanate50 favoured the formation of the undesired C7 
carbamate 48, with extensive experimentation failing to overturn this result. Interestingly 
enough, we observed that esterification or silylation proceeded with high selectivity at the C9 325 
position. This hinted that it was indeed the more reactive position, with the carbamoylating 
agent behaving anomalously. Leveraging this finding, a sequence involving bis-silylation, 
selective C9 desilylation, followed by treatment with trichloroacetyl chloride and C7 
desilylation successfully led to (–)-leiodermatolide (2) in 23 steps and 3.2% overall yield.59 
Careful comparison with the authentic sample provided by the Wright group confirmed that 330 
they were identical in all respects. Serendipitously, this 3D structure corresponds exactly to 
the one out of four stereoisomers arbitrarily rendered in our isolation paper.42 At this point, 
we could embark on a programme of SAR studies and further biological evaluation of this 
promising anticancer lead structure.65 
23 
 335 
Scheme 12. Fragment union and completion of (–)-leiodermatolide (2) 
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Rhizopodin  
Rhizopodin (3) is an architecturally complex macrocyclic polyketide first isolated in 340 
1993 by Höfle and Reichenbach from the myxobacterium Myxococcus stipitatus.66 By binding 
with and inhibiting actin polymerisation, rhizopodin mediates potent antiproliferative activity 
as well as strong cytostatic effects against a range of cancer cell lines.67 This selective 
interaction with actin also enabled its structural elucidation, with X-ray crystallographic 
studies of the bound rhizopodin-actin complex revealing an intriguing C2-symmetric 345 
macrodiolide.68 From a structural perspective, 14 of the 18 stereocentres are embedded in the 
38-membered macrolide core, together with two oxazole rings and two diene motifs, with the 
remaining four stereocentres located on the two side chains.69 The ornate architecture and 
promising anticancer profile of rhizopodin has rendered intensive research towards its total 
synthesis. Although several groups have reported the synthesis of various substructures,70–74 350 
there has only been two completed total syntheses of the target structure itself.75–77 
Our proposed synthesis (Scheme 13) of rhizopodin (3) centred on structural 
simplification into the truncated monomer 69 and known side chain fragment 70.78 This 
disconnection provided a degree of flexibility, with macrocycle formation possible via direct 
or sequential esterification, followed by bidirectional aldol coupling with ketone 70 to 355 
incorporate the requisite side chain(s). Oxazole formation was envisaged via amide bond 
formation between C14-C22 acid 71 and C8-C13 amino alcohol 72 followed by dehydration, 
while diene installation was proposed using a Stille coupling of vinyl iodide 73 and a suitable 
C8 stannane.  
As is often the case with complex polyketide synthesis, the strategic incorporation of 360 
orthogonal protecting groups was of crucial importance. Initially, we envisaged incorporating 
PMB ethers to chemoselectively unmask the required alcohols for the macrolactonisation and 
side chain attachment. However, we found that an oxidative PMB ether cleavage using DDQ 
25 
resulted in the concomitant oxidation of the C5 allylic methyl ether, with alternative Lewis 
acidic cleavage degrading our advanced intermediates.77 As such, we opted for a carefully 365 
selected combination of silyl protecting groups. Notably, attempts at deprotecting the C16-
OTBS ethers in the endgame resulted solely in eliminated product. Frustratingly also, attempts 
at deprotecting a primary C22-OTIPS ether to allow side-chain installation, in the presence of 
a secondary C16-OTES ether, resulted in simultaneous cleavage of both silyl groups. These 
difficulties ultimately forced us to opt for a riskier gamut of silyl protecting groups in acid 71 370 
and aldehyde 73 (vide infra). 
  
Scheme 13. Retrosynthetic analysis of rhizopodin (3). Disconnection (1) refers to an 
esterification/macrolactonisation, disconnection (2) refers to an aldol/dehydration/reduction sequence 
Synthesis of the C14-C22 carboxylic acid 71 commenced with a Brown allylation onto 375 
Roche ester-derived aldehyde 74 (Scheme 14A).79 The remaining stereocentres in this 
fragment were generated first via a Mukaiyama aldol reaction between aldehyde 75 and silyl 
ketene acetal 76, setting up the C18 stereocentre, and a subsequent diastereoselective 
reduction80 of the cyclic ketone after methanolysis of dioxinone 77. From β-hydroxylactone 
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78, subsequent protections and oxidation afforded the C14-C22 acid 71. The amino-alcohol 380 
coupling partner 72 required for the oxazole formation was formed from propargyl alcohol 79 
(Scheme 14B). A Sharpless asymmetric epoxidation (yielding epoxide 80)81,82 followed by 
amidation and regioselective epoxide opening gave oxazoline 81. A final sequence of 
methylation and hydrolysis then delivered the amino alcohol 72. 
The final C1-C7 fragment 73 required for the macrocycle was obtained by an 385 
enantioselective Mukaiyama aldol reaction between aldehyde 82 and Chan’s diene (83) 
(Scheme 14C).83,84 Subsequent methanolysis of dioxinone 84 followed by a Narasaka 
reduction85 generated the free diol. Protecting group manipulations and a final methylation of 
the free C5-OH then afforded the required Stille coupling partner 73. 
 390 
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Scheme 14. A) Synthesis of the C14-C22 carboxylic acid 71. B) Synthesis of the C8-C13 amino alcohol 
72.  C) Synthesis of the C1-C7 vinyl iodide 73 
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28 
Fragment assembly commenced with an amide bond formation between carboxylic acid 
71 and amino alcohol 72 (Scheme 15). Employing modified Robinson-Gabriel conditions 395 
developed by Wipf,86 oxazole 85 was formed cleanly. Subsequent stannylation afforded vinyl 
stannane 86, which was coupled with vinyl iodide 73 via a Stille cross-coupling63 to give the 
truncated monomer in anticipation for the key macrocyclisation step. At this stage, we 
discovered that a series of oxidation state adjustments and protecting group manipulations 
were critical for the success of the macrocycle formation. While conditions required for 400 
methyl ester hydrolysis concomitantly unmasked the required C18-OH, Yamaguchi 
macrolactonisation conditions39 disappointingly afforded a mixture of oligomers, primarily 
corresponding to the monomeric truncate. As such, we were forced to adopt a stepwise 
approach to access both coupling partners for the macrolactonisation. A controlled reduction 
to the aldehyde 87 therefore was performed, meaning that this key intermediate could be 405 
subjected to either a controlled C18-OTMS desilylation (88) or a Pinnick oxidation to afford 
seco-acid 89.  
29 
 
Scheme 15. Synthesis of the truncated C1-C22 monomers 
 410 
Following these manoeuvres, a selective esterification between alcohol 88 and seco-acid 
89 served to complete the linear carbon skeleton in 90 (Scheme 16). This was followed by a 
similar sequence of desilylation, oxidation and macrolactonisation to close the required 
macrocycle 91. The C2-symmetry of the molecule presented the opportunity of performing a 
bidirectional side-chain installation in the endgame. This required a selective C22-22’ primary 415 
TBS ether cleavage, a capricious operation owing to the presence of multiple secondary silyl 
protecting groups of similar lability. In the end, carefully controlled exposure of the protected 
macrocycle 91 to HF/py selectively afforded the C22/22’ diol 92 which, following oxidation, 
underwent a double boron-mediated aldol addition with ketone 70.78 Drawing from our 
reidispongiolide synthesis,78 a sequence involving a controlled dehydration,87 followed by a 420 
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conjugate reduction and global deprotection concluded our synthesis of rhizopodin (3) in 29 
steps in 0.2% overall yield.77 The eventual success of this project required judicious fine-
tuning of the protecting group strategy and redox steps, emphasising the need for perseverance 
based on a flexible synthesis plan. 
 425 
Scheme 16. Fragment union and completion of the total synthesis of rhizopodin (3) 
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Chivosazole F 
Following their discovery of rhizopodin, Höfle and Reichenbach reported the isolation 430 
of chivosazoles A-F from the myxobacterium Sorangium cellulosum in 1995.88,89 The 
chivosazoles are a structurally unprecedented class of polyene macrolides, with each member 
of the family differing in terms of the substitution at C11 and C20. Notably, the chivosazole 
family displayed potent inhibitory activity against filamentous fungi, yeast and a panel of 
human cancer cell lines. This bioactivity stems from its selective inhibition of actin 435 
polymerisation. Intriguingly, the lack of structural homology to other known actin-binders 
suggests that the chivosazoles may have a distinct mode of action.90,91 What ignited our 
interest in the chivosazoles as a synthetic target was their astounding array of structural 
features (Scheme 17). Specifically, all congeners as typified by chivosazole F (4) possess a 
31-membered macrolactone, containing 10 stereocentres and an oxazole moiety. However, 440 
the most impressive feature is the set of conjugated polyenes with alternating geometry in the 
macrocycle: a (Z,E,Z,E)-C2-C9 tetraene, a (Z,E)-C12-C15 diene and an (E,E,Z)-C23-C28 
triene regions.92 These polyene regions demanded careful handling of sensitive late-stage 
intermediates and mild reaction conditions, necessary to suppress both potential olefin 
isomerisation and degradation pathways. Perhaps as a reflection of the challenges imposed by 445 
this demanding target, only two total syntheses of chivosazole F (4), including our approach 
described below, have been reported to date.93,94 
Our synthetic approach needed to address the delicate nature of the chivosazole 
structure; in particular, the isomerisation-prone (2Z,4E,6Z,8E)-tetraene. Therefore, we sought 
to minimise the number of endgame transformations. To this end, we envisaged a highly 450 
convergent approach towards accessing the full carbon skeleton by employing site-selective 
cross-couplings. This broadly disconnects the full carbon skeleton to reveal the C14-C35 
northern hemisphere and the C1-C13 southern hemisphere of the natural product. 
32 
The success of this strategy crucially relied on the judicious choice of coupling handles 
and cross-coupling conditions. Building on initial intelligence gathering studies, we 455 
discovered that the Stille cross-coupling provided the most efficient means of fragment union. 
We also anticipated that a late-stage macrolactonisation might generate the macrocycle. This 
analysis revealed four constituent fragments – the C1-C5 fragment 93, the C6-C13 fragment 
94, the C14-C26 fragment 95 and the C27-C35 fragment 96. 
 460 
Scheme 17. Initial synthetic strategy towards chivosazole F (4) and the four proposed fragments 
Recognising the 19,22-syn relationship, synthesis of the C14-C26 bis-halide linchpin  
commenced with an asymmetric boron-mediated aldol reaction from methyl ketone 97 and 
aldehyde 98 95,96 to afford b-hydroxyketone 99 (Scheme 18A). This was then subjected to 
Evans-Tishchenko reduction56 to establish the remaining stereocentre. The oxazoline ring was 465 
cyclised using DAST97 following amide formation from carboxylic acid 100 and amino 
alcohol 101.98 From oxazoline 102, oxazole formation using MnO2 proved incompatible with 
the pendant vinyl iodide functionality, suggesting that this oxidation step should be conducted 
post-fragment assembly. Beginning from the ethyl ketone derivative 103 of (S)-Roche ester 
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33 
and known aldehyde 104,99,100 a boron-mediated aldol reaction101 readily installed the C31 470 
and C32 stereocentres in b-hydroxyketone 105, with an Evans-Tishchenko reduction again 
employed to set the final C30 stereocentre (Scheme 18B). A six-step sequence revealed 
aldehyde 106, which was subjected to a Stork-Zhao olefination, deprotection and stannylation 
to afford the required stannane 96.49 
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Scheme 18. A) Synthesis of the C14-C26 bis-halide linchpin 102. B) Synthesis of the C27-C35 vinyl 
stannane 96 
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34 
ketene aminal 107 (derived from imide 108) with aldehyde 109 forged the two stereocentres 480 
in the C7-C13 fragment 110 (Scheme 19).103 Subsequent Stork-Zhao olefination of aldehyde 
111 installed the terminal (6Z)-vinyl iodide in 112, which then engaged in a site-selective 
Stille cross-coupling with stannane 93 to afford the C1-C13 southern hemisphere 113 in 
preparation for exploring the planned fragment coupling sequence. 
 485 
 
Scheme 19. Synthesis of the C1-C13 southern hemisphere fragment 113 
 
With the two hemispheres in hand, we looked towards effecting the site-selective Stille 
coupling between the stannane 114 derived from 113 and bis-halide 102. Unfortunately, not 490 
only did this fail to effect the required coupling, it also highlighted the propensity for the 
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conditions (Scheme 20B). To avoid handling the isomerisation-prone (2Z) olefin, we next 495 
investigated the possibility of achieving a late-stage macro-olefination with a pendant 
phosphonate ester at C30 in 118. The revised synthesis of the southern hemisphere thus 
involved a Stille coupling with vinyl iodide 94 and stannane 120 (Scheme 20C). 
 
36 
 500 
Scheme 20. A) Initial attempts at fragment union under Stille conditions failed to deliver the product and 
resulted in isomerisation of the tetraenoate. B) Esterification of alcohol 115 to the C1-C5 acid 116 resulted in 
concomitant isomerisation of the C2 olefin C) Our revised synthetic approach to chivosazole F (4) 
Using optimised Stille cross-coupling conditions, and rationalising chemoselective 
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37 
of tBu3P104 was required to prevent isomerisation of the (6Z)-alkene. These conditions also 
allowed for the successful site-selective formation of the C13-C14 bond between bis-halide 
102 and vinyl stannane 120, as well elaborating the resulting vinyl bromide 121 with the C27-
C35 fragment 118 (derived from vinyl iodide 122), with complete control of alkene geometry 510 
throughout the process. This success led us to ponder whether we could turn this into a one-
pot process. Remarkably, with sequential addition of each fragment (i. 119, ii. 94, iii. 102 and 
iv. 118), we were able to assemble the full carbon skeleton of the chivosazoles in 123 in one 
pot in 56% yield (82% per coupling step). At this advanced stage, the (4E,6Z,8E)-triene was 
found to be highly prone to isomerisation on attempting to adjust the oxidation state at C3 515 
ahead of the planned Horner-Wadsworth-Emmons (HWE) type macro-olefination. 
Furthermore, model studies on the planned Ando-olefination105 gave poor control over the 
desired 2Z geometry. This series of disappointing and incredibly frustrating setbacks forced 
us to return to the drawing board… 
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 520 
Scheme 21. Employing the site-selective Stille coupling strategy to form the chivosazole backbone 
 
The challenges imposed by the delicate triene necessitated us to reconfigure our 
choreography of fragment coupling to an end-stage macro-Stille cyclisation (Scheme 22). 
Furthermore, to access the (2Z) geometry, an alternative olefination strategy was required. 525 
The anticipated lability of the target molecule also prompted us to switch from an acetonide 
to a silylene protecting group for the 32,34-diol to facilitate a mild final deprotection. These 
alterations meant that our constituent fragments towards assembling 4 would involve a C3-C5 
aldehyde 124, a revised C7-C13 stannane 125 and a revised C27-C35 phosphonate 126. 
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Scheme 22. Final strategy adopted towards the total synthesis of chivosazole F (4) 
 
The revised C27-C35 phosphonate 126 was made from diol 127,94 an intermediate used 
in our previous routes. Building on the prior work, fragment coupling could be conducted in 
a stepwise manner (via the C7-C26 vinyl bromide 128) or a one-pot process (i. 102 ii. 125 iii. 535 
126) to efficiently deliver the advanced fragment 129 (Scheme 23). Gratifyingly, employing 
the Still-Gennari type phosphonate afforded useful selectivities towards the desired 2Z 
geometry for the HWE olefination with aldehyde 124.106,107 At this stage, a double oxidation 
of the C7-OH and the oxazoline was carried out using MnO2, notably accomplishing the 
challenging aromatisation on a delicate advanced fragment. Subsequently, the resulting 540 
aldehyde 130 was elaborated via a Stork-Zhao olefination to furnish the full carbon skeleton 
and also the seco precursor for the ring-closing intramolecular Stille reaction. To our delight, 
the critical macrocyclisation delivered the protected natural product with complete retention 
of olefin geometry. A final global deprotection concluded our total synthesis of chivosazole F 
(4) in 20 steps and 2.5% overall yield. Our success in this arduous campaign hinged upon 545 
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careful initial analysis and planning, which fortunately, allowed for a highly convergent 
approach and a succinct endgame sequence. While we recognised the potential lability of such 
advanced polyene fragments, we could not have anticipated the frustration it brought. In this 
case, it truly stressed the importance of a flexible, modular strategy and the ability to adapt 
the strategy as required.  550 
 
 
Scheme 23. Revised fragment coupling and completion of the total synthesis of chivosazole F (4) 
OH
35
OH OTBS
PMBO
27
35
OO O Si
Me3Sn
1
O
PO
OCH2CF3
OCH2CF3
tBu tBu
127
126
7
13
OTES
Bu3Sn
Pd(PPh3)4
CuTC
83%
O N
26
MeO
OTBS
14
I
Br
O N
26
MeO
OTBS
14
Br
13
7
OTES
102
Pd(PPh3)4, CuTC
88%
129
O N
26
MeO
OTBS
14
13 OTES
27
35
OO O Si1
O
P
OCH2CF3
OCH2CF3
tBu tBu
O
102 + 125 + 126
one-pot
80%
29%, 8 steps
OH
OH
Pd(PPh3),
CuTC
OH
a) NaH
b) MnO2
Bu3Sn 29%
Z/E 2.5 : 1
O N
26
MeO
OTBS
14
13
7
OTES
27
35
OO O Si1
O tBu tBu
O
5
Bu3Sn
a) [PPh3CH2I]I, NaHMDS
b) Pd(PPh3)4, CuTC
c) HF•py
41%, 3 steps
Chivosazole F (4)
O N
6
5
35
OHO
1 O
MeO
OH
OH
OH
125
130
128
O
H
124
H
41 
Conclusions 
Our recent synthetic endeavours towards these highly challenging classes of complex 555 
polyketides not only showcases the versatility of our group’s aldol methodology, but also 
highlights the trials and tribulations we overcame in a sustained campaign to achieve these 
enticing targets. In our total synthesis of spirastrellolide A methyl ester, we discovered that the 
subtle, unexpected structural effects imposed by distal protecting groups proved to be highly 
consequential in the critical macrolactonisation. Similarly, for rhizopodin, a carefully 560 
choreographed sequence of protecting group incorporation and selective deprotection, was 
pivotal to achieving the target. Our campaign towards leiodermatolide underlines the need to 
reassess fragment coupling strategies when required. This is a common theme and important 
lesson – and was certainly a defining obstacle in our campaign towards chivosazole F. In the 
end, a carefully orchestrated sequence of fragment coupling steps proved to be vital for success. 565 
 In this account, the highlighted setbacks and accompanying explanations of strategy 
evolution serve to illuminate the unanticipated difficulties that can make or break a total 
synthesis. Overall, we are provided with a humbling reminder that despite continual advances 
in the field of chemical synthesis, there is still much to be learned from tackling a structurally 
complex natural product.  570 
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